New Solid-State Analysis Capabilities

New Solid-State Analysis Capabilities

News

Home > News > New Solid-State Capabilities
New Diffractometer at Enantia for solid state analysis and solid state development

Enantia enhances its Solid-State Capabilities with the acquisition of the Empyrean X-Ray Diffractometer

March 31st, 2025

Enantia is pleased to announce the acquisition of the Empyrean X-ray diffractometer by Malvern Panalytical, further strengthening our solid-state analysis capabilities. This state-of-the-art instrument enhances our ability to characterize and analyze polymorphs, cocrystals and salts, with the highest sensitivity, reinforcing our expertise in solid-state screening and development.

The Empyrean X-ray diffractometer is a versatile and high-performance system, enabling advanced characterization of drug substances and drug products at various stages of drug development.

Its cutting-edge technology allows for detailed structural analysis in solid form development, crystallization process optimization, and intellectual property strategy.

In addition to the Empyrean, Enantia also operates the Aeris X-ray diffractometer (fully dedicated to High Potent APIs), further expanding our capabilities in solid-state characterization.

INVACO Acquires ENANTIA

INVACO Acquires ENANTIA

News

Home > News > INVACO Acquires ENANTIA

Enantia will be at the DCAT week to discuss with our US customers our services in chemistry and solid form development.

INVACO Acquires ENANTIA to Drive Expansion and Growth in Specialized CRO Services

Barcelona, January 29th, 2025

Enantia, a leading contract research organization (CRO) with over 20 years of experience in chemistry services, has been fully acquired by INVACO, a company controlled by the venture capital fund Inveready Biotech IV, which specializes in life sciences and health. This strategic acquisition marks the beginning of an ambitious growth plan, including the integration of specialized small CROs to provide comprehensive R&D services.

The transaction includes the participation of Enantia’s management team as shareholders, reinforcing their commitment to the company’s future. The collaboration between Enantia and Inveready will facilitate expansion into new markets while executing a targeted acquisition strategy to consolidate a group of highly specialized CROs serving the pharmaceutical, biotech, and materials industries.

Operating from its facilities at the Parc Científic de Barcelona and Esplugues de Llobregat, Enantia has built a strong reputation in medicinal chemistry, chemical process development, and solid-state R&D. With a team of highly skilled professionals, the company provides high-quality research and development services to an international client base.

 

Joan Feixas, CEO of Enantia, commented:

“We are grateful for Inveready’s trust in Enantia and our management team to lead the creation of a specialized R&D services group. This partnership comes at the right moment and under the right circumstances to drive significant growth. We are excited to be part of this project and look forward to expanding our impact in life sciences and beyond.”

 

Sara Secall, Partner at Inveready, stated:

“The preclinical CRO sector in Spain is highly fragmented. We created INVACO with the goal of acquiring specialized CROs in life sciences, and Enantia is the first step in building a stronger and more integrated group. This acquisition provides an exit for historical shareholders while ensuring the commitment of Enantia’s management team, who now hold a stake in INVACO. Our plan is to integrate additional CROs focused on preclinical drug development, including formulations, analytical and bioanalytical methods, toxicology, and pilot production.”

About Enantia

Founded in 2003 as a spin-off from the University of Barcelona, Enantia is a CRO specialized in chemical process R&D, solid-state R&D, and medicinal chemistry. The company has contributed to nearly 100 patent applications resulting from its research, collaborating annually with over 40 international pharmaceutical, biotech, and CDMO clients.

About Inveready

Inveready is a leading investment firm specializing in alternative assets, wealth management, and investment funds, managing over €1.9 billion. With a strong presence in the Spanish SME market, the firm has received multiple industry recognitions, including Best Venture Capital Firm (2017) by SpainCap and Best European Venture Debt Fund (2023) by Preqin. Inveready operates from its headquarters in San Sebastián, with additional offices in Barcelona and Madrid.

Enantia at Drug Discovery Chemistry Europe 2024

Enantia at Drug Discovery Chemistry Europe 2024

News

Home > News > Enantia at Drug Discovery Chemistry

Enantia will be at the DCAT week to discuss with our US customers our services in chemistry and solid form development.

Enantia at Drug Discovery Chemistry Europe 2024

November 28th, 2024

Enantia is thrilled to announce our participation in Drug Discovery Chemistry, taking place in Barcelona, Spain, from December 3rd to 5th, 2024. As a company based in Barcelona, we are proud to welcome the first edition of Drug Discovery Chemistry to our vibrant city, offering a unique opportunity to connect with industry leaders and showcase our expertise in drug discovery.

Enantia’s medchem platform combines innovative thinking, cutting edge facilities, and a team of experts commited to delivering high-quality, reliable results. Whether you need hit-to-led support, focused compound libraries or preliminary solid form selection, we are your trusted partner in drug discovery and medicinal chemistry.

Arrange a meeting with us through info@enantia.com or via LinkedIn.

Let’s connect and explore collaboration opportunities!

Enantia at CPhI Worldwide 2024

Enantia at CPhI Worldwide 2024

News

Home > News > Enantia at CPhI Worldwide 2024

Enantia will be at the DCAT week to discuss with our US customers our services in chemistry and solid form development.

Enantia at CPhI Milan 2024

October 1st, 2024

Enantia is excited to announce our participation in CPhI Worldwide 2024, hold in Milan, from October 8th to 10th, 2024. This globally event unites key players in the pharmaceutical and chemical industries, and we are eager to present our advanced capabilities.

As a leading CRO, in Process ChemistrySolid Form Development and Medicinal Chemistry, we have been committed to meet our clients’ needs regarding the research and development of Small Organic Molecules, including Highly Potent APIs, since 2003. Whether you’re looking for support in Process ChemistrySolid Form Development or Medicinal Chemistry, our team is here to move your chemical development forward.

Arrange a meeting with us through info@enantia.com or via LinkedIn.

We will be glad to meet you and explore new synergies together.

Enantia at ChemOutsourcing 2024

Enantia at ChemOutsourcing 2024

News

Home > News > Enantia at ChemOutsourcing 2024

Enantia will be at the DCAT week to discuss with our US customers our services in chemistry and solid form development.

Enantia at ChemOutsourcing 2024

July 29th, 2024

Enantia will be attending ChemOutsourcing 2024, taking place in Parsippany, New Jersey, between September 9th and 11th, 2024. This premier event brings together experts from the pharmaceutical and chemical industries, and we’re excited to showcase our advanced capabilities.

With our broad expertise in chiral chemistry and cocrystals, Enantia delivers tailored solutions to complex challenges. Whether it’s early-stage chemistry, process chemistry, or solid state development, our team is ready to help you accelerate project timelines while ensuring precision and quality.

Arrange a meeting with us through info@enantia.com or via LinkedIn.

Let’s connect in ChemOutsourcing and discuss how we can collaborate to drive your projects forward!

Enantia at DCAT week

Enantia at DCAT week

News

Home > News > Enantia at DCAT week 2024

Enantia will be at the DCAT week to discuss with our US customers our services in chemistry and solid form development.

Enantia at DCAT Week 2024

February 15th, 2024

Enantia will be in New York city for this year’s edition of the DCAT week, taking place between March 18th and 21st 2024.

For over two decades we have been dedicated to fulfill our clients’ requirements on Small Organic Molecules through extensive chemical research and development, encompassing even Highly Potent APIs (HPAPIs). Take advantage of our broad expertise in Process Chemistry and Co-Crystallization Technology to move your chemical development forward.

Arrange a meeting with us through info@enantia.com or via LinkedIn.

Looking forward to speaking with you in NYC!

Flow chemistry available at Enantia

Flow chemistry available at Enantia

News

Home > News > Flow chemistry available at Enantia

Flow Chemistry equipment at Enantia for chemical development services like route scouting, optimization and scale-up. CMC services. Medicinal chemistry services.

Enantia is proud to announce the inclusion of continuous flow chemistry for our Process Chemistry projects and our Medicinal Chemistry services

February 12th, 2024

Enantia is proud to offer flow chemistry as part of our services in medicinal chemistry and CMC development.

Flow chemistry has been a well-established technology in the petrochemical and bulk commodity industries for decades. Surprisingly, it has not been until recent years that it has gained an increasingly important role and interest in the manufacture of complex active pharmaceutical ingredients (APIs). As a result of this, flow chemistry has become a powerful enabling tool, complementary to traditional batch manufacturing, for the pharmaceutical and fine chemical industries to develop more sustainable, safe, environmentally friendly and efficient chemical processes.

With the inclusion of flow chemistry to our portfolio of innovative technologies, we aim to provide comprehensive services in the development of routes of synthesis, process optimization and scale up of key intermediates and API manufacturing processes. This will complement and strengthen our activities in chemistry, manufacturing, and control (CMC).

The advantages of flow chemistry enable the successful performance of processes that, otherwise, would not be feasible at industrial scale in batch reactors. For example:

  • Processes requiring accurate controlled conditions
  • Processes with hazardous reagents or intermediates
  • Processes carried out under extreme conditions of temperature or pressure
  • Photocatalytic processes

In addition, flow chemistry integrates into Enantia’s medicinal chemistry platform as an additional tool to support the company’s MedChem services.

Enantia offers the flow chemistry services in partnership with Alza&Associates, a sustainable chemistry consulting company. We combine Enantia’s extensive experience in chemical R&D of drug substances with A&A’s extensive experience and deep flow chemistry knowledge to provide a unique, industry-oriented service.

Read more here about our flow chemistry capabilities and equipment.

Enantia’s Presence at BioSpain 2023

Enantia’s Presence at BioSpain 2023

News

Home > News > Enantia’s Presence at BioSpain 2023

Enantia attended the current edition of BioSpain, the main national biotech event and one of the most important in Europe

Enantia’s presence at BIOSPAIN 2023

September 29th, 2023

Enantia attended the current edition of BIOSPAIN, the main national biotech event and one of the most important in Europe, attracting over 850 entities seeking collaboration opportunities in the field of drug development.

From September 26th to 28th, we engaged with the dynamic biotech community and explore ground-breaking opportunities for collaboration.

We discussed our services in Medicinal Chemistry (design and synthesis of focused libraries), Process Chemistry (such as route scouting and CMC support), Solid Form Screening and Development (optimizing candidate properties, improving IP and obtaining purification processes) and Solid Form Analysis (for a detailed understanding of the solid phase in the development and manufacturing of APIs and fine chemicals).

If you missed connecting with us at the event, discover how Enantia can support your project at info@enantia.com.

We’re committed to advancing innovation in drug discovery in the biotech and pharma industry!

Enantia at BOS Basel 2023

Enantia at BOS Basel 2023

Home > News > Enantia at BOS Basel 2023
Enantia at CPhI

Enantia at BOS Basel 2023

July 4th and 5th, 2023

Enantia is attending this year’s edition of BOS Basel, taking place the 4th and 5th of July.

As a leading CRO in Process Chemistry, Solid Form Development and Medicinal Chemistry, we have been committed to meet our clients’ needs regarding the research and development of Small Organic Molecules, including Highly Potent APIs, since 2003. Our strengths as key providers of CMC services are:

  • Optimizing, scaling-up and impurity profiling of routes of synthesis
  • Purification technologies based on crystallizations and cocrystallizations
  • Solid Form Development (being pioneers in the screening of cocrystals) and Solid Form Analysis

Find us through the partnering platform and at info@enantia.com. We will be glad to meet you to explore new synergies together.

See you in Basel!

Enantia has once again been granted the CIR from the French authorities

Enantia has once again been granted the CIR from the French authorities

News

Home > News > CIR granted to Enantia

CIR Enantia CRO cocrystals chemical development

Enantia has once again been granted the CIR from the French authorities

January 25th, 2023

The French Ministry of Higher Education and Research has granted Enantia with the Crédit d’Impôt Recherche (CIR) (i.e., R&D tax credit) for a further three-year period: 2023, 2024 and 2025.

Thanks to the support of Crédit d’Impôt Recherche, French companies can incur research and development costs and be partially reimbursed for these expenses. The objective of this measure is to promote business innovation and competitiveness at national and international level.

We are glad to share this great news with our French customers, especially those with a strong R&D activity. This includes pharmaceutical companies, biotechs, CDMOs and CMOs, which can benefit from our CIR accreditation in all our services, such as medicinal chemistry, chemical development, solid state development and solid form analysis.

You can find our CIR accreditation here.